Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma. [electronic resource]
Producer: 20150521Description: 507-18 p. digitalISSN:- 1432-0851
- Adult
- Aged
- Aged, 80 and over
- Antigens, Neoplasm -- immunology
- Antineoplastic Agents, Alkylating -- administration & dosage
- CD4-Positive T-Lymphocytes -- immunology
- Cancer Vaccines -- administration & dosage
- Cholesterol -- immunology
- Cohort Studies
- Combined Modality Therapy
- Cyclophosphamide -- administration & dosage
- Dose-Response Relationship, Drug
- Drug Combinations
- Female
- Follow-Up Studies
- Humans
- Lymphatic Metastasis
- Male
- Melanoma -- immunology
- Membrane Proteins -- immunology
- Middle Aged
- Neoplasm Staging
- Phospholipids -- immunology
- Prognosis
- Saponins -- immunology
- T-Lymphocytes, Regulatory -- immunology
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.